Читать книгу Diagnóstico y tratamiento de la infección por el virus de la inmunodeficiencia humana, Infecciones oportunistas y trastornos relacionados - Rosa Nohemí Terán Terán - Страница 22

BIBLIOGRAFÍA

1.Wheeler E, Seager K. Ageing with HIV. Aust Nurs midwifery J. 2015;22(7):26–9.

2.Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. Vol. 20, AIDS. 2006. p. 2165–74.

3.Erlandson KM, Lake JE, Sim M, Falutz J, Prado CM, Domingues R, et al. Infected Women Compared to Men. 2019;77(July 2017):288–94.

4.Gonciulea A, Wang R, Althoff KN, Palella FJ, Lake J, Kingsley LA, et al. An increased rate of fracture occurs a decade earlier in HIV+ compared with HIV-men. Aids. 2017;31(10):1435–43.

5.Martínez E, Jódar Gimeno E, Reyes García R, Carpintero P, Casado JL, Del Pino Montes J, et al. Documento de consenso: Recomendaciones para el manejo de la enfermedad ósea metabólica en pacientes con virus de la inmunodeficiencia humana. Enferm Infec Microbiol Clin. 2014;32(4):250–8.

6.Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int. 2018;29(3):595–613.

7.Kelesidis T, Currier JS, Yang OO, Brown TT. Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. AIDS Rev. 2014;16(3):123–33.

8.Güerri-Fernández R, Lerma-Chippirraz E, Fernandez Marron A, García-Giralt N, Villar-García J, Soldado-Folgado J, et al. Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate. Aids. 2018;32(7):913–20.

9.Biver E, Calmy A, Aubry-Rozier B, Birkhäuser M, Bischoff-Ferrari HA, Ferrari S, et al. Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis. Osteoporos Int. 2019;30(5):1125–35.

10.Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. Aids. 2009;23(12):1519–29.

11.Brown TT, Hoy J, Borderi M, Guaraldi G, Renjifo B, Vescini F, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60(8):1242–51.

12.World Health Organization. Who Scientific Group on the Assessment of Osteoporosis At Primary Health. World Health [Internet]. 2007;May(May 2004):1–13. Available from: http://www.who.int/chp/topics/Osteoporosis.pdf

13.Mazzotta E, Ursini T, Agostinone A, Di Nicola AD, Polilli E, Sozio F, et al. Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: Sensitivity and specificity of current guidelines on bone mineral density management. AIDS Patient Care STDS. 2015;29(4):169–80.

14.Tsai MS, Zhang JY, Sun HY, Liu WC, Wu PY, Yang CJ, et al. Performance of fracture risk assessment tool in HIV-positive male individuals aged ≥45 years on suppressive antiretroviral therapy. J Int AIDS Soc. 2019;22(8):4–11.